aiqbench analysis
FDARxBench establishes a critical new standard for evaluating large language models on high-stakes regulatory and clinical reasoning tasks using FDA drug labels. The benchmark exposes significant limitations in current models regarding factual grounding, long-context retrieval, and safe refusal behaviors when processing heterogeneous medical data. This work is essential for advancing the reliability of AI systems intended for healthcare compliance and patient safety applications.
FDARxBench: Benchmarking Regulatory and Clinical Reasoning on FDA Generic Drug Assessment
arXiv:2603.19539v2 Announce Type: replace Abstract: We introduce an expert curated, real-world benchmark for evaluating document-grounded question-answering (QA) motivated by generic drug assessment, using the U.S. Food and Drug Administration (FDA) drug label documents. Drug labels contain rich but heterogeneous clinical and regulatory information, making accurate question answering difficult for current language models. In collaboration with FDA regulatory assessors, we introduce FDARxBench, and construct a multi-stage pipeline for generating high-quality, expert curated, QA examples spanning factual, multi-hop, and refusal tasks, and design evaluation protocols to assess both open-book and closed-book reasoning. Experiments across proprietary and open-weight models reveal substantial gaps in factual grounding, long-context retrieval, and safe refusal behavior. While motivated by FDA generic drug assessment needs, this benchmark also provides a substantial foundation for challenging regulatory-grade evaluation of label comprehension. The benchmark is designed to support evaluation of LLM behavior on drug-label questions.
Abstract:We introduce an expert curated, real-world benchmark for evaluating document-grounded question-answering (QA) motivated by generic drug assessment, using the U.S. Food and Drug Administration (FDA) drug label documents. Drug labels contain rich but heterogeneous clinical and regulatory information, making accurate question answering difficult for current language models. In collaboration with FDA regulatory assessors, we introduce FDARxBench, and construct a multi-stage pipeline for generating high-quality, expert curated, QA examples spanning factual, multi-hop, and refusal tasks, and design evaluation protocols to assess both open-book and closed-book reasoning. Experiments across proprietary and open-weight models reveal substantial gaps in factual grounding, long-context retrieval, and safe refusal behavior. While motivated by FDA generic drug assessment needs, this benchmark also provides a substantial foundation for challenging regulatory-grade evaluation of label comprehension. The benchmark is designed to support evaluation of LLM behavior on drug-label questions.
Computation and Language (cs.CL); Artificial Intelligence (cs.AI)
arXiv:2603.19539 [cs.CL]
(or arXiv:2603.19539v2 [cs.CL] for this version)
https://doi.org/10.48550/arXiv.2603.19539 Focus to learn more arXiv-issued DOI via DataCite
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Full text under the publisher's open licence · 234 words
Related coverage

Reducing medical claims review time with AI on AWS: The EXL Medical IDP solution
AWS · Sep 21, 2026

XtalPi Holdings Limited: XtalPi Holdings Announces 2026 Interim Results
finanznachrichten.de · Aug 19, 2026

[AINews] Reality Checks on AI News (Yegge shuts down Gas Town, Databricks’ +60% Astra cost)
Latent Space · Sep 17, 2026
TrialAtlas: Multi-Agent Research Organization for Clinical Trial Design and Optimization
arXiv · Sep 21, 2026